Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.07 USD | -2.69% | +7.76% | +23.06% |
05-13 | Oppenheimer Adjusts Achieve Life Sciences Price Target to $11 From $18, Maintains Outperform Rating | MT |
05-09 | Transcript : Achieve Life Sciences, Inc., Q1 2024 Earnings Call, May 09, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+23.06% | 178M | |
+33.37% | 49.46B | |
+1.55% | 42.58B | |
+49.11% | 42.49B | |
-4.22% | 29.09B | |
+11.57% | 26.61B | |
-21.00% | 18.64B | |
+7.36% | 13.16B | |
+28.30% | 12.55B | |
+23.80% | 12.1B |
- Stock Market
- Equities
- ACHV Stock
- News Achieve Life Sciences, Inc.
- Achieve Life Sciences Reports 'Positive' Topline Results From Phase 2 Trial of Cytisinicline for Vaping Cessation